Strides Phrama announces 33% YOY growth

▴ strides-phrama-announces-dividend-33-growth
Strides pharma declares 33% growth and 26% increase in revenue

Strides Pharma announced their Q4 results along with the FY20 financial results.According to the declaration to BSE company reported a strong performance in FY20 despite Ranitidine withdrawal from the US market.

The highlights of the performance as shared by the Company are as below

Adjusted FY20 revenues at ₹29,127 million with 33% YoY growth, Reported revenues grew by 26% FY20 Adjusted EBITDA at ₹6,514 million, translating into 22.4% EBITDA margins and YoY growth of 153% Reported EBITDA at ₹5,276 million delivering 19.1% EBITDA margins and 105% YoY growth Regulated markets clocked 47% revenue growth in FY20 US business meets higher end of FY20 guidance Adjusted for Ranitidine withdrawal, Q4FY20 performance in line with expectation board recommended dividend of ₹2/- per share resulting in the total dividend for  the year at ₹14/- per share (140%)
Commenting on the performance, Dr R Ananthanarayanan, CEO & MD, remarked, “The financial year 2020 has metall strategic and financial outcomes for Strides in spite of the unexpected US FDA direction to withdraw Ranitidine on the last day of FY20. While we have grown our revenues by 26% (33% Adjusted), our EBITDA has grown over two times, demonstrating over 740 basis point (1,070 basis point Adjusted) improvement in the margins.
We are also satisfied that the regulated markets continued its healthy track record and our US business met the upper end of our FY20 outlook, including the revenues from Ranitidine.We have entered into a new world order with Covid-19, the magnitude and scale of which remains indeterminate. We have maintained our agility and responsiveness to deal with this situation and are pursuing our commitment to 3Psviz- Patients, People and Purpose. We are determined to play a substantial role in society by bringing affordable andquality healthcare to millions of people around the globe. We strongly believe that our businesses will maintaintraction and would grow significantly to culminate into a healthy financial outcome for Strides in FY21.”

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global
pharmaceutical company headquartered in Bangalore, India. The Company mainly operates in the regulated
markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded
markets. The Company’s global manufacturing sites are located in India- Bangalore (two sites), Pondicherry, and
Chennai, Singapore, Italy- Milan, Kenya- Nairobi and US-Florida. The Company focusses on “difficult to manufacture”
products that are sold in over 100 countries
Tags : #StridePharma #Ranitidine #YOY #Q4results #FY20

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Surviving Against the Odds: Steven Spinale's Journey After an Ingrown Hair Turns DeadlyMarch 29, 2024
10 reasons why media research and Planning are essential in Healthcare marketingMarch 29, 2024
The Surprising Link Between Sleep and Age Perception: What You Need to KnowMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 StudyMarch 29, 2024
Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024